影响慢性粒细胞白血病生存期因素的临床分析

将存活5年以上的23例慢性粒细胞白血病(慢粒)患者与同期生存时间少于5年的40例慢粒患者的临床特点进行了对照分析,慢粒患者初诊时的年龄、性别、血红蛋白、血小板、外周血嗜碱细胞、骨髓巨核细胞以及外周血和骨髓原粒细胞+早幼粒细胞与生存期关系不大(p>0.05),而脾肿大与生存期有明显关系(p<0.05)。白细胞较高者预后并不一定恶劣。接受马利兰治疗累积剂量及达到缓解所需时间与慢粒生存期的关系也不大(p>0.05),而马利兰所致骨髓抑制对延长生存期似有一定影响,首次缓解持续时间与生存期有明显关系(p<0.01)。马利兰与靛玉红交替使用可能是一种对延长生存期有益的治疗方案。

INFLUENTIAL FACTORS ON SURVIVAL LENGTH OF CASES OF CHRONIC GRANULOCYTIC LEUKEMIA

Contrast analysis was made on clinical manifestations of 23 cases ofchronic granulocytic leukemia (CGL)who survived for more than 5 yearsand 40 cases of CGL who survived for less than 5 years in the sameperiod.Such factors in the cases of CGL on the first visit as ages,sexes,hemoglobin,thrombocytes,peripheric blood basophilic cells,bone marrowmegslocaryocytes,peripheric blood,bone marrow myeloblasts and prog-ranulocytes had not much to do with the survival length,while spleno-megaly had a great deal to do with it (P<0.05).The prognosis of thosecases whose leucocyte count was rather high was not bound to be bad.The cumulative dose of myleran and the time needed for remission hadnot much to do with the survival length (P>0.05).However,the arrestof bone marrow caused by myleran probably had something to do withprolonging survival length.The duration of the first remission obviouslyhad something to do with the survival length (P<0.01).The alternativeadministration of myleran aped indirubin might be a good therapeuticplan to be helpful to prolonging survival length